Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyski...Show More
peer of
Metrics
marketSTOCKS
msh_idCOM:NEWRON
localeit
websitehttps://www.newron.com/
ipo_date2014-06-17
primary_stock_msh_idSIX:NWRN
source_ref215d45b7-8057-4d7f-894b-641db9090652
products_or_servicesDevelopment of therapies for central and peripheral nervous system diseases, including marketed products and clinical development candidates.